Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Umeclidinium/Vilanterol vs Fluticasone Propionate/Salmeterol in COPD
NCT01879410Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of Anoro Ellipta in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Change From Baseline in 0 to 24 Hour Weighted Mean Forced Expiratory Volume Over 1 Second. Started Jun 2013; status: completed.
02
Drugs
Anoro Ellipta
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01879410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01879410.